Ex-CEO Behind Bars, 10x’s Clinical Ambitions, and Pharma’s AI Gambit

We kick off the very first episode of 2026 with a major legal development. This week, the former CEO of CytoDyn was sentenced to 30 months in prison, more than a year after being convicted on multiple charges including four counts of securities fraud, two counts of wire fraud, and three counts of insider trading. Also, we examine recent investments in artificial intelligence by several major drugmakers, and where they are hoping the technology can make an impact. Then, the latest from 10x Genomics and its plans to expand into clinical diagnostics through new collaboration. And for some research news, a new study that explores how functional forms of amyloid can create stable memories.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

Ex-CytoDyn CEO Sentenced to 30-Month Prison Term on Fraud, Insider Trading

By Alex Philippidis, GEN, January 27, 2026

Pharma Bets Big on AI Platforms with Flurry of New Year Deals

By Fay Lin, PhD, GEN Edge, January 22, 2026

JPM: Nvidia Launches AI Collaborations with Eli Lilly, Thermo Fisher

By Alex Philippidis, GEN Edge, January 13, 2026

Clinical Ambitions: 10x Expands Beyond Research with Trio of Collaborations

By Alex Philippidis, GEN Edge, January 26, 2026

Chai’s the Limit for AI Antibody Designer After $130M Series B Funding

By Alex Philippidis, GEN Edge, December 16, 2025

Lilly Expands AI Ties to Insilico, from Customer to Drug Discovery Partner